**SUPPLEMENTARY MATERIAL**

Table S1. Baseline characteristics of randomized subjects. Reproduced with permission from Yuji Kawagichi, Jun Sawa, Noriko Sakuma, et al. Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec in patients with type 2 diabetes: A randomized, open­label, cross-over study using continuous glucose monitoring profiles. JDI. 2019; 10:343-351.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Overall  (n = 30) | Gla300/Deg (n = 15) | Deg/Gla300  (n = 15) | p-value\* |
| Age (years) | 69.5 ± 11.3 | 71.1 ± 9.2 | 67.9 ± 13.2 | 0.449 |
| Duration of diabetes (years) | 18.3 ± 11.3 | 18.5 ± 10.4 | 18.1 ± 12.5 | 0.937 |
| Sex, Male, n (%) | 18 (60.0) | 8 (53.3) | 10 (66.7) | 0.151 |
| BMI (kg/m2) | 24.6 ± 4.8 | 25.3 ± 4.8 | 24.0 ± 5.0 | 0.468 |
| HbA1c (%) | 8.2 ± 1.9 | 8.5 ± 2.2 | 8.0 ± 1.5 | 0.469 |
| S-CPR (ng/mL) | 1.8 ± 1.7 | 1.9 ± 1.8 | 1.8 ± 1.6 | 0.883 |
| eGFR (mL/min/1.73 m2) | 67.9 ± 22.7 | 66.6 ± 25.0 | 69.1 ± 20.8 | 0.763 |
| S-albumin (g/dL) | 3.7 ± 0.5 | 3.8 ± 0.5 | 3.7 ± 0.5 | 0.589 |
| Prestudy treatment  OADs only, n  Basal/bolus insulin, n  Basal insulin dosage (U/day)  Bolus insulin dosage (U/day)  Basal insulin ± OADs, n  Basal insulin dosage (U/day)  Premixed insulin, n  Dosage (U/day) | 13  5  13.6 ± 15.1  16.8 ± 9.1  4  15.5 ± 10.0  8  21.3 ± 9.2 | 6  3  6.0 ± 3.5  12.0 ± 4.0  2  22.0 ± 11.3  4  21.0 ± 9.6 | 7  2  25.0 ± 21.2  24.0 ± 11.3  2  9.0 ± 1.4  4  21.5 ± 10.2 | 0.337  0.374  0.196  0.170  1.000  0.248  1.000  0.946 |
| Antidiabetic agents other than insulin  DPP4 inhibitor, n  Metformin, n  SGLT2 inhibitor, n  Sulfonylurea, n  Glinide, n  α-GI, n  GLP-1RA, n | 14  10  2  3  1  3  1 | 7  3  2  2  1  1  1 | 7  7  0  1  0  2  0 | 1.000  0.123  0.153  0.559  0.326  0.559  0.326 |

BMI, body mass index; HbA1c, glycated hemoglobin; S-CPR, serum C-peptide immunoreactivity; eGFR, estimated glomerular filtration rate; s-alb, serum albumin; OADs, oral antidiabetic drugs; DPP4, dipeptidyl peptidase-4; SGLT2, sodium-glucose cotransporter; α-GI, alpha-glucosidase inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist. Values are expressed as means ± SD. \*Data were compared using the Student’s t-test or chi-squared test. A p-value of <0.05 was considered significant. Antidiabetic drugs other than insulin were not changed throughout the study period.